| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Optimal 
-emitters: Zalutsky summarizes challenges in identifying appropriate radionuclides for targeted -particle therapy and highlights articles in this issue on the potential of -labeled monoclonal antibodies in cancer treatment.
Page 1238
Pathologic response prediction: Cascini and colleagues assess the predictive value of changes in tumor 18F-FDG uptake on PET during and after preoperative radiochemotherapy in patients with locally advanced rectal cancer.
Page 1241
Pinpointing prostate disease: Reske and colleagues evaluate the ability of 11C-choline PET/CT to identify prostate carcinoma and to differentiate cancer tissue from normal prostate, benign prostate hyperplasia, and focal chronic prostatitis.
Page 1249
|
Significant information added: Yuan and colleagues compare 18F-FDG PET/CT with side-by-side PET and CT images in the diagnosis of locoregional lymph node metastases in patients with esophageal squamous cell cancer.
Page 1255
Recommended as routine: Pryma and colleagues study the value of 18F-FDG PET as part of initial postoperative staging and subsequent monitoring in patients with Hürthle cell thyroid cancer.
Page 1260
Characterizing disease progression: Bruzzi and colleagues evaluate the utility of PET/CT for detection of Richter's transformation of chronic lymphocytic leukemia into diffuse large cell lymphoma and assess the significance of these findings for prompt diagnosis and optimal management.
Page 1267
|
Spine imaging with PET: Rosen and colleagues report on the prevalence of abnormal spinal 18F-FDG uptake and the relationship between findings on PET and the severity of degenerative spinal disease on CT.
Page 1274
|
Targeting lung fibrosis: Lebtahi and colleagues investigate the expression of somatostatin receptors in the lungs of patients with idiopathic pulmonary fibrosis and correlate 111In-octreotide uptake on SPECT with conventional functional and radiologic assessments of the condition.
Page 1281
|
SPECT vs. CT in LV metrics: Schepis and colleagues compare the relative capabilities of 99mTc-gated SPECT and ECG-gated 64-slice CT in the assessment of left ventricular dimensions, muscle mass, and function in patients being evaluated for coronary artery disease.
Page 1288
Intracardiac stem cell therapy: Kang and colleagues employ PET to investigate the targeting capabilities and tissue distribution of intracoronary-injected peripheral hematopoietic stem cells labeled with 18F-FDG in patients with myocardial infarction.
Page 1295
|
Obesity cardiac risk quantified: Elhendy and colleagues report on the accuracy of routine stress 99mTc-tetrofosmin myocardial perfusion imaging in predicting cardiac risk and overall mortality in patients who are obese.
Page 1302
Identifying myocardial viability: Slart and colleagues use both 18F-FDG and 13N-ammonia PET to evaluate the effects of nitrate administration on blood flow to chronically dysfunctional but viable myocardium in patients with chronic ischemic left ventricular dysfunction.
Page 1307
More than attenuation correction: Goetze and colleagues review the frequency and significance of abnormal findings on the "nondiagnostic" CT portion of cardiac SPECT/CT scans in 200 patients.
Page 1312
Predicting antidepressive therapy response: Joe and colleagues use 99mTc-HMPAO SPECT to investigate progressive regional cerebral blood flow differences in patients who do and do not respond to citalopram therapy for major depression.
Page 1319
PET in lymphoma: Jhanwar and Straus provide a comprehensive review of the role of 18F-FDG in the management of patients with lymphoma and discuss the potential for other PET tracers in accurately staging disease and predicting response to therapy.
Page 1326
Targeted therapy in leukemia: Glatting and colleagues evaluate the suitability of a 90Y-labeled anti-CD45 monoclonal antibody for selectively delivering radiation to hematopoietic tissues in patients with refractory or relapsing acute myelogenous leukemia.
Page 1335
|
Enhanced effects of -emitters: Elgqvist and colleagues investigate the efficacy of radioimmunotherapy using 211At-labeled compounds in advanced ovarian cancer in a mouse model.
Page 1342
|
Assessing RFA response: Okuma and colleagues characterize normal lung tissue after radiofrequency ablation in a rabbit model and report on the suitability of dedicated small-animal PET for monitoring early therapeutic effects of ablation on lung tumors.
Page 1351
Novel PET tracer: Madar and colleagues explore in a canine model the kinetics and myocardial and whole-body biodistribution of an 18F-labeled lipophilic cation for PET imaging.
Page 1359
|
Imaging cardiac damage: Zhao and colleagues report on the development of a novel radiotracer designed to image apoptosis and necrosis in a rat model of reperfused acute myocardial infarction.
Page 1367
|
Thyroid treatment monitoring: Lubberink and colleagues determine the influence of large amounts of 131I on PET image quality in the serial 124I assessment of radiation dosimetry in therapy for thyroid cancer.
Page 1375
Cross-talk in thyroidal uptake: Bläser and colleagues conduct in vitro investigations on the mechanisms of signal transduction in 18F-FDG and radioiodide uptake in an experimental thyroid cell line.
Page 1382
| ON THE COVER
Precise and reliable assessment of left ventricular function and dimensions is prognostically important in cardiac patients. Comparison of SPECT and multislice CT for such assessments is pertinent because of the availability of hybrid scanners combining the 2 techniques. SPECT and multislice CT have been found to agree well over a wide range of clinically relevant values for left ventricular ejection fraction and functional parameters, but interchangeable use of the 2 techniques should be avoided for left ventricular volume, muscle mass, and regional wall motion.
SEE PAGE 1290
|
Related articles in JNM:
-Particle Therapy of Microscopic Disease: Providing a Further Rationale for Clinical Investigation
-Radioimmunotherapy of Intraperitoneally Growing OVCAR-3 Tumors of Variable Dimensions: Outcome Related to Measured Tumor Size and Mean Absorbed Dose
| ||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
